Pathologic Features of Anti-Mi-2 Dermatomyositis

被引:30
|
作者
Tanboon, Jantima [1 ,2 ]
Inoue, Michio [1 ,2 ]
Hirakawa, Shinya [2 ,4 ]
Tachimori, Hisateru [4 ]
Hayashi, Shinichiro [1 ]
Noguchi, Satoru [1 ]
Suzuki, Shigeaki [5 ]
Okiyama, Naoko [6 ]
Fujimoto, Manabu [6 ,7 ]
Nishino, Ichizo [1 ,2 ,3 ]
机构
[1] Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo, Japan
[2] Natl Ctr Neurol & Psychiat, Dept Genome Med Dev, Med Genome Ctr, Kodaira, Tokyo, Japan
[3] Natl Ctr Neurol & Psychiat, Clin Genome Anal, Med Genome Ctr, Kodaira, Tokyo, Japan
[4] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo, Japan
[5] Keio Univ, Sch Med, Dept Neurol, Tokyo, Japan
[6] Univ Tsukuba, Fac Med, Dept Dermatol, Ibaraki, Japan
[7] Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan
关键词
ANTI-SYNTHETASE SYNDROME; SKELETAL-MUSCLE; TNF-ALPHA; AUTOANTIBODIES; EXPRESSION; MYOPATHIES; IL-1-BETA; BIOMARKER; MYOSITIS;
D O I
10.1212/WNL.0000000000011269
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To identify the characteristic pathologic features of dermatomyositis (DM) associated with anti-Mi-2 autoantibodies (anti-Mi-2 DM). Methods We reviewed 188 muscle biopsies from patients (1) pathologically diagnosed with DM through the sarcoplasmic expression for the myxovirus-resistant protein A and (2) serologically positive for 1 of 5 DM-specific autoantibodies (DMSAs) (anti-Mi-2, n = 30; other DMSAs, n = 152) or negative for all 5 DMSAs (n = 6). We then compared the histopathologic and immunohistochemical features of patients with anti-Mi-2 DM to those with non-Mi-2 DM and patients with anti-synthetase syndrome (ASS) (n = 212) using the t test, Fisher exact test, and a logistic regression model. Results Patients with anti-Mi-2 DM showed significantly higher severity scores in muscle fiber and inflammatory domains than non-Mi-2 DM patients. The presence of perifascicular necrosis, increased perimysial alkaline phosphatase activity, and sarcolemmal membrane attack complex deposition was more frequent in patients with anti-Mi-2 DM (p < 0.01). After Bonferroni correction, there were no significant differences in the percentages of the features mentioned above between the patients with anti-Mi-2 DM and those with ASS (p > 0.01). Conclusion Perifascicular necrosis and perimysial pathology, features previously reported in ASS, are common in patients with anti-Mi-2 DM. Our findings not only assist in differentiating anti-Mi-2 DM from other DM subtypes but also suggest the possibility of an overlapping mechanism between anti-Mi-2 DM and ASS. Classification of Evidence This study provides Class II evidence that the muscle biopsies of DM patients with anti-Mi-2 autoantibodies are more likely to demonstrate higher severity scores in muscle fiber and inflammatory domains.
引用
收藏
页码:E448 / E459
页数:12
相关论文
共 50 条
  • [1] Pathologic Features of Anti-Mi-2 Dermatomyositis (vol 96, pg e448, 2021)
    Tanboon, J.
    Inoue, M.
    Hirakawa, S.
    NEUROLOGY, 2023, 100 (15) : 738 - 738
  • [2] Anti-Mi-2 dermatomyositis with ulcerative plaques
    David Palacios-Diaz, Rodolfo
    Abril-Perez, Carlos
    Estebanez, Andrea
    Gegundez-Hernandez, Hector
    Angel Navarro-Mira, Miguel
    Botella-Estrada, Rafael
    RHEUMATOLOGY, 2022, 61 (10) : E326 - E327
  • [3] Anti-Mi-2 antibody titers and cutaneous manifestations in dermatomyositis
    Ogawa-Momohara, Mariko
    Muro, Yoshinao
    Akiyama, Masashi
    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2019, 2 (02) : 49 - 52
  • [4] Four cases of anti-Mi-2 antibody-positive dermatomyositis: relationship between anti-Mi-2 antibody titre and disease severity and activity
    Matsuda, T.
    Ueda-Hayakawa, I.
    Kambe, N.
    Son, Y.
    Ozaki, Y.
    Hamaguchi, Y.
    Takehara, K.
    Fujimoto, M.
    Okamoto, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (06) : E233 - E234
  • [5] Anti-Mi-2 antibodies
    Ghirardello, A
    Zampieri, S
    Iaccarino, L
    Tarricone, E
    Bendo, R
    Gambari, PF
    Doria, A
    AUTOIMMUNITY, 2005, 38 (01) : 79 - 83
  • [6] A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies
    Ito, Mitsuru
    Moriya, Chie
    Matsuyama, Kanako
    Shu, En
    Hamaguchi, Yasuhito
    Seishima, Mariko
    CASE REPORTS IN DERMATOLOGY, 2020, 12 (02): : 92 - 97
  • [7] A case of cancer-associated amyopathic dermatomyositis with anti-Mi-2 antibody
    Nakamura, Ryusuke
    Okamura, Ken
    Watabe, Takahiro
    Miura, Takahiro
    Suzuki, Tamio
    JOURNAL OF DERMATOLOGY, 2025, 52 (04): : e280 - e281
  • [8] Anti-Mi-2 antibody-positive dermatomyositis following Spirulina intake
    Kuzumi, Ai
    Yoshizaki, Ayumi
    Kawanabe, Ruriko
    Sato, Shinichi
    RHEUMATOLOGY, 2024, 63 (09) : e264 - e265
  • [9] Detection of anti-Mi-2 autoantibodies before dermatomyositis-specific manifestations
    Vulsteke, Jean-Baptiste
    Blockmans, Daniel
    Moons, Veronique
    Vijgen, Sara
    Bossuyt, Xavier
    De Langhe, Ellen
    RHEUMATOLOGY, 2020, 59 (10) : E60 - E62
  • [10] Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis
    Komura, K
    Fujimoto, M
    Matsushita, T
    Kaji, K
    Kondo, M
    Hirano, T
    Orito, H
    Horikawa, M
    Hamaguchi, Y
    Hasegawa, M
    Takehara, K
    Sato, S
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2005, 40 (03) : 215 - 217